Abstract: |
Radiopharmaceuticals have gained increased clinical utility in recent years, particularly in the field of oncology. These successes have generated an un-precedented interest in clinical translation of completely novel agents, which are comprised of a variety of radionuclides and vector molecules. Due to the unique nature of radiopharmaceuticals such as short shelf life and high potency, clinical evaluations of these agents pose some challenges from the regulatory and practical point of view. The authors of this chapter provide an overview of those challenges as well as recommendations on how some of these challenges could be addressed. In particular, emphasis is placed on the description of the regulatory landscape governing the performance of clinical trials with radiopharmaceuticals in the United States, on key considerations for the operational requirements of radiopharmaceutical production facilities, and on requirements for dispensing, drug handling, and operations at the clinical site. © 2022 Elsevier Inc. All rights reserved. |